This is supported by evidence that intravenous administration of MVA (thus increasing the number of sites of T cell activation across the entire mouse) leads to higher CD8+ T cell responses in the spleen and liver (25; A. J. Spencer and A. V. S. Hill, unpublished data), in addition to reports of improved immunogenicity of cancer vaccines by increasing the number of injection sites (39). The gene discussed is CD8A; the disease is cancer.